Literature DB >> 7852345

Invariant chain induces a delayed transport from early to late endosomes.

J P Gorvel1, J M Escola, E Stang, O Bakke.   

Abstract

Invariant chain associated with class II molecules is proteolytically processed in several distinct intermediates during its transport through the endocytic pathway. Using subcellular fractionation, early and late endosomal compartments were separated in human fibroblasts transfected with HLA-DR (4N5 cells) and supertransfected with invariant chain (4N5Ii cells) or invariant chain lacking most of the cytoplasmic tail (4N5 delta 20Ii cells). Early and late endosome membrane fractions were characterized by morphology and by analyzing the presence of the Rab5 and Rab7 GTPases as markers of early and late endosomes, respectively. The transfer of endocytosed horseradish peroxidase from early to late endosomes proceeded relatively rapid both in 4N5 and 4N5 delta 20Ii cells (t1/2 = 25 min), whereas this transfer was significantly delayed (t1/2 = 2 h) in 4N5Ii cells. Pulse-chase experiments showed that invariant chain and its degradation products were first observed in early endosomes and thereafter in late endosomes. Our results strongly suggest that invariant chain induces a retention mechanism in the endocytic pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7852345     DOI: 10.1074/jbc.270.6.2741

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  The cytoplasmic tail of invariant chain regulates endosome fusion and morphology.

Authors:  Tommy W Nordeng; Tone F Gregers; Thomas Lasker Kongsvik; Stéphane Méresse; Jean-Pierre Gorvel; Fabrice Jourdan; Andrea Motta; Oddmund Bakke
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

2.  Uncoating ATPase Hsc70 is recruited by invariant chain and controls the size of endocytic compartments.

Authors:  Cécile Lagaudrière-Gesbert; Sherri L Newmyer; Tone F Gregers; Oddmund Bakke; Hidde L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

3.  Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.

Authors:  T Bevec; V Stoka; G Pungercic; I Dolenc; V Turk
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

Review 4.  Melanosomes and MHC class II antigen-processing compartments: a tinted view of intracellular trafficking and immunity.

Authors:  Michael S Marks; Alexander C Theos; Graça Raposo
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  Human immunodeficiency virus type 1 nef expression prevents AP-2-mediated internalization of the major histocompatibility complex class II-associated invariant chain.

Authors:  Hélène Toussaint; François-Xavier Gobert; Michael Schindler; Carina Banning; Patrycja Kozik; Mabel Jouve; Frank Kirchhoff; Philippe Benaroch
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

6.  The TIP30 protein complex, arachidonic acid and coenzyme A are required for vesicle membrane fusion.

Authors:  Chengliang Zhang; Aimin Li; Shenglan Gao; Xinchun Zhang; Hua Xiao
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

7.  Endosomal binding kinetics of Eps15 and Hrs specifically regulate the degradation of RTKs.

Authors:  Linda Hofstad Haugen; Frode Miltzow Skjeldal; Trygve Bergeland; Oddmund Bakke
Journal:  Sci Rep       Date:  2017-12-21       Impact factor: 4.379

8.  Inhibition of invariant chain (Ii)-calnexin interaction results in enhanced degradation of Ii but does not prevent the assembly of alpha beta Ii complexes.

Authors:  P Romagnoli; R N Germain
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

Review 9.  Exposing the Specific Roles of the Invariant Chain Isoforms in Shaping the MHC Class II Peptidome.

Authors:  Jean-Simon Fortin; Maryse Cloutier; Jacques Thibodeau
Journal:  Front Immunol       Date:  2013-12-13       Impact factor: 7.561

Review 10.  Proteolysis and antigen presentation by MHC class II molecules.

Authors:  Paula Wolf Bryant; Ana-Maria Lennon-Duménil; Edda Fiebiger; Cécile Lagaudrière-Gesbert; Hidde L Ploegh
Journal:  Adv Immunol       Date:  2002       Impact factor: 3.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.